Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund

Executive Summary

Harvard Pilgrim Chief Medical Officer Michael Sherman said the full warranty behind the agreement is the right kind of deal to balance access and cost.


Related Content

The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics
Amgen Faces New ICER Roadblock To Repatha Reimbursement
Repatha Pricing Pressure Might Actually Increase After Outcomes Trial
AstraZeneca's 13 Outcomes-Based Contracts Show “Proactive" Engagement On New Models
US Outcomes-Based Contracts In Oncology? CAR-T Could Be Case Study
HHS Action On Drug Pricing: Here's Who Secretary Price Is Listening To
Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance
Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math
Will Physician Demand For Repatha Put Pressure On Payer Restrictions?
Amgen's Repatha Pricing Deal With Harvard Pilgrim Hinges On Results, Utilization


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts